Asia
Japan
Kyoto
Kyoto University - Center for iPS Cell Research and Application (CiRA) - Department of Cell Growth and Differentiation
Principal Investigator: Noriyuki Tsumaki
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Dr. Tsumaki's team focuses on basic research for bone and cartilage diseases using induced Pluripotent Stem Cells (iPS). Regarding achondroplasia, they research mainly on the mechanisms that control chondrocyte differentiation and proliferation, on the mechanisms through which skeletal dysplasias are caused, searching for drug candidates for these diseases.
Most recent publications regarding achondroplasia:
- Yamashita, A., et al., Statin treatment rescues FGFR3 skeletal dysplasia phenotypes. Nature, 2014. 513(7519): p. 507-11. Available here.
Nagoya
Nagoya University Graduate School of Medicine - Musculoskeletal and Cutaneous Medicine - Orthopaedics/Rheumatology
Principal Investigator: Naoki Ishiguro
Contact: Hiroshi Kitoh
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Regarding achondroplasia, Dr. Ishiguro's team focuses on drug repositioning for this disease, for which they identified meclozine, which is sold over-the-counter for motion sickness treatment.
Most recent publications regarding achondroplasia:
- Matsushita, M., et al., Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia. Sci Rep, 2017. 7(1): p. 7371. Available here.
- Matsushita, M., et al., Low bone mineral density in achondroplasia and hypochondroplasia. Pediatr Int, 2016. 58(8): p. 705-8. Available here.
